TrialBlood2010

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Jonathan W Friedberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.